In this endocrinology month in review for March 2024, we recap the most popular FDA news and pipeline updates as well as recognizing the 2-year anniversary of Diabetes Dialogue.
A new study has shown that semaglutide can significantly reduce the risk of major adverse cardiovascular events in patients even for those who don't have diabetes.The Big Picture: Dr. Adriana
Health: FDA approves Novo Nordisk's Wegovy for lowering heart risks gdnonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gdnonline.com Daily Mail and Mail on Sunday newspapers.
A new study has shown that semaglutide can significantly reduce the risk of major adverse cardiovascular events in patients even for those who don't have diabetes.The Big Picture: Dr. Adriana
A new study has shown that semaglutide can significantly reduce the risk of major adverse cardiovascular events in patients even for those who don't have diabetes.The Big Picture: Dr. Adriana
A new study has shown that semaglutide can significantly reduce the risk of major adverse cardiovascular events in patients even for those who don't have diabetes.The Big Picture: Dr. Adriana
A new study has shown that semaglutide can significantly reduce the risk of major adverse cardiovascular events in patients even for those who don't have diabetes.The Big Picture: Dr. Adriana
A new study has shown that semaglutide can significantly reduce the risk of major adverse cardiovascular events in patients even for those who don't have diabetes.The Big Picture: Dr. Adriana
A new study has shown that semaglutide can significantly reduce the risk of major adverse cardiovascular events in patients even for those who don't have diabetes.The Big Picture: Dr. Adriana